145 related articles for article (PubMed ID: 33384162)
1. Bempedoic Acid: A New Tool in the Battle Against Hyperlipidemia.
Powell J; Piszczatoski C
Clin Ther; 2021 Feb; 43(2):410-420. PubMed ID: 33384162
[TBL] [Abstract][Full Text] [Related]
2. Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside.
Agarwala A; Quispe R; Goldberg AC; Michos ED
Drug Des Devel Ther; 2021; 15():1955-1963. PubMed ID: 34007155
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials.
Duell PB; Banach M; Catapano AL; Laufs U; Mancini GBJ; Ray KK; Broestl C; Zhang Y; Lei L; Goldberg AC
J Clin Lipidol; 2024; 18(2):e153-e165. PubMed ID: 38341323
[TBL] [Abstract][Full Text] [Related]
4. Role of Bempedoic Acid in Clinical Practice.
Ballantyne CM; Bays H; Catapano AL; Goldberg A; Ray KK; Saseen JJ
Cardiovasc Drugs Ther; 2021 Aug; 35(4):853-864. PubMed ID: 33818688
[TBL] [Abstract][Full Text] [Related]
5. Bempedoic Acid: How Will It Shape the Future Lipid-Lowering Landscape? Mode of Action, Evidence, and Clinical Use.
Drexel H; Mader A
Cardiology; 2024; 149(1):71-77. PubMed ID: 37989119
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the efficacy and safety of bempedoic acid in women and men: Pooled analyses from phase 3 trials.
Goldberg AC; Banach M; Catapano AL; Duell PB; Leiter LA; Hanselman JC; Lei L; Mancini GBJ
Atherosclerosis; 2023 Nov; 384():117192. PubMed ID: 37648637
[TBL] [Abstract][Full Text] [Related]
7. How Will Our Practice Change After the CLEAR Outcomes Trial?
Abrahams T; Nelson AJ; Nicholls SJ
Curr Atheroscler Rep; 2024 Mar; 26(3):83-89. PubMed ID: 38294660
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of bempedoic acid among patients with statin intolerance and those without: A meta-analysis and a systematic randomized controlled trial review.
Li Y; Gao H; Zhao J; Ma L; Hu D
PLoS One; 2024; 19(1):e0297854. PubMed ID: 38277431
[TBL] [Abstract][Full Text] [Related]
9. Effect of Bempedoic Acid on Serum Uric Acid and Related Outcomes: A Systematic Review and Meta-analysis of the available Phase 2 and Phase 3 Clinical Studies.
Cicero AFG; Pontremoli R; Fogacci F; Viazzi F; Borghi C
Drug Saf; 2020 Aug; 43(8):727-736. PubMed ID: 32358698
[TBL] [Abstract][Full Text] [Related]
10. Effects of bempedoic acid on markers of inflammation and Lp(a).
Reddy S; Deoker A
Curr Opin Cardiol; 2024 Jul; 39(4):280-285. PubMed ID: 38456474
[TBL] [Abstract][Full Text] [Related]
11. A new indication for bempedoic acid (Nexletol).
Med Lett Drugs Ther; 2024 May; 66(1702):75-77. PubMed ID: 38696311
[No Abstract] [Full Text] [Related]
12. Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance.
Bays HE; Bloedon LT; Lin G; Powell HA; Louie MJ; Nicholls SJ; Lincoff AM; Nissen SE
J Clin Lipidol; 2024; 18(1):e59-e69. PubMed ID: 37951797
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of bempedoic acid lipid-lowering therapy: a systematic review and meta-analysis of randomized controlled trials.
Venkatraman S; Das S; Eerike M; Cherian JJ; Bagepally BS
Eur J Clin Pharmacol; 2023 Nov; 79(11):1453-1463. PubMed ID: 37672112
[TBL] [Abstract][Full Text] [Related]
14. Bempedoic Acid can Reduce Cardiovascular Events in Combination with Statins or As Monotherapy: A Systematic Review and Meta-analysis.
Zhang J; Guan X; Zhang B; Wang J; Jin X; Zhao Y; Li B
Am J Cardiovasc Drugs; 2023 Nov; 23(6):695-708. PubMed ID: 37672202
[TBL] [Abstract][Full Text] [Related]
15. Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review.
Ferri N; Ruscica M; Fazio S; Corsini A
J Clin Med; 2024 Feb; 13(4):. PubMed ID: 38398257
[TBL] [Abstract][Full Text] [Related]
16. Impact of Bempedoic Acid on Cardiovascular Outcomes by Sex.
Cho L; Plutzky J; Brennan D; Louie MJ; Lei L; Robinson P; Powell HA; Nicholls SJ; Lincoff AM; Nissen SE
Circulation; 2024 May; 149(22):1775-1777. PubMed ID: 38581406
[No Abstract] [Full Text] [Related]
17. Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023.
Katsiki N; Filippatos T; Vlachopoulos C; Panagiotakos D; Milionis H; Tselepis A; Garoufi A; Rallidis L; Richter D; Nomikos T; Kolovou G; Kypreos K; Chrysohoou C; Tziomalos K; Skoumas I; Koutagiar I; Attilakos A; Papagianni M; Boutari C; Kotsis V; Pitsavos C; Elisaf M; Tsioufis K; Liberopoulos E
Atheroscler Plus; 2024 Mar; 55():74-92. PubMed ID: 38425675
[TBL] [Abstract][Full Text] [Related]
18. Assessing the Role of Bempedoic Acid in Lipid-Lowering Therapy.
Fernandez-Vazquez D; Weideman S; Banerjee S
Am J Cardiol; 2024 Apr; 216():93-94. PubMed ID: 38369175
[No Abstract] [Full Text] [Related]
19. Effect of bempedoic acid on mortality and cardiovascular events in primary and secondary prevention: A post-hoc analysis of the CLEAR-outcomes trial.
Sayed A; Brophy JM
Int J Cardiol; 2024 Jul; 406():132074. PubMed ID: 38643794
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
